Results 71 to 80 of about 47,670 (237)
Quantitative Assessment of Visible Nigrosome‐1 in Patients with Parkinson's Disease
Movement Disorders Clinical Practice, EarlyView.Abstract Background The nigrosome‐1 (N1) sign on susceptibility‐weighted imaging (SWI) typically disappears in Parkinson's disease (PD), though some patients can show uni−/bilaterally preserved N1. Objective Investigating whether visible nigrosomes in PD patients differ from those of healthy subjects (HC). Methods Forty‐eight PD and 35 HC underwent 3 T‐
Maria Eugenia Caligiuri +10 more
wiley +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Visuospatial deficits in Parkinson's disease (PD) often precede dementia and complicate daily functioning. Alzheimer's disease (AD) pathology and α‐synuclein aggregation frequently co‐occur in PD, but their combined impact on cognition is unclear.
David Ledingham +8 more
wiley +1 more source
Early detection of Alzheimer's disease using the MEMORIES mnemonic
Chronic Diseases and Translational MedicineThe rising incidence and death rates linked to Alzheimer's disease (AD) highlight an urgent issue. Genetic screening is celebrated as a significant advancement for its early detection capabilities, pinpointing those at risk before the emergence of ...
Valentinus Besin, Farizky M. Humardani
doaj +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Non‐motor symptoms, especially autonomic dysfunction, are major contributors to disability and decreased quality of life in Parkinson's disease (PD). Despite being common and having a wide range of clinical facets, exocrine gland dysfunction is still not well recognized and managed.
Renato P. Munhoz +2 more
wiley +1 more source
Focused Ultrasound for the Treatment of Circuit and Molecular Pathology in Parkinson's Disease
Movement Disorders, EarlyView.Abstract Focused ultrasound is rapidly emerging as a novel technology for the development of symptomatic therapies and supporting disease‐modifying treatments for Parkinson's disease (PD). At the forefront of this development is thermoablation using high‐intensity focused ultrasound, an incisionless treatment that has been extensively tested in ...
Rikke Hahn Kofoed +7 more
wiley +1 more source
Novel Variants Linked to the Prodromal Stage of Parkinson’s Disease (PD) Patients
DiagnosticsBackground and objective: The symptoms of most neurodegenerative diseases, including Parkinson’s disease (PD), usually do not occur until substantial neuronal loss occurs. This makes the process of early diagnosis very challenging.
Marwa T. Badawy +2 more
doaj +1 more source
Pathogenic or Likely Pathogenic GRN Variants Are Found in 0.1% of Parkinson's Disease Patients
Movement Disorders, EarlyView.Abstract Background Parkinsonism may be observed in multiple neurodegenerative diseases, including GRN‐associated frontotemporal dementia (FTD‐GRN), complicating the differential diagnosis of Parkinson's disease (PD). Objectives To investigate the presence of GRN variants in a large group of PD patients.
Christian A. Ganoza +31 more
wiley +1 more source
Movement Disorders, EarlyView.Abstract Background Recent advances in proteomic profiling have enabled its use as a powerful approach in elucidating molecular mechanisms underlying Parkinson's disease, enabling the identification of disease‐associated protein alterations and candidate biomarkers for diagnosis, progression, and therapeutic response.
Victoria J. Dardov +21 more
wiley +1 more source
Movement Disorders, EarlyView.Abstract Background The cerebrospinal fluid alpha‐synuclein seed amplification assay (CSFasynSAA) detects alpha‐synuclein aggregation in over 90% of individuals with sporadic PD (sPD). However, the clinical characteristics of sPD with negative CSFasynSAA remain undefined.
Sarah M. Brooker +30 more
wiley +1 more source
Prodromal Alzheimer's disease can affect activities of daily living for adults with Down syndrome
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease MonitoringINTRODUCTION Alzheimer's disease (AD) affecting adults with Down syndrome (DS‐AD), like late‐onset AD (LOAD) in the neurotypical population, has preclinical, prodromal, and more advanced stages.
Tracy A. Listwan +8 more
doaj +1 more source